Management of Hyperparathyroidism and Multiple Myeloma

Initial Assessment and Diagnosis

Evaluate renal function through creatinine clearance, as both conditions can cause renal impairment, in patients with concurrent hyperparathyroidism and multiple myeloma 2
Assess for bone disease through appropriate imaging (CT or MRI) to identify both lytic lesions from multiple myeloma and bone changes from hyperparathyroidism 3
Check for hypercalcemia-related symptoms including polyuria, gastrointestinal disturbances, dehydration, and decreased glomerular filtration rate in patients with hyperparathyroidism and multiple myeloma 1

Provide aggressive hydration as first-line treatment for hypercalcemia from either cause, according to the National Comprehensive Cancer Network 1
Administer bisphosphonates, with zoledronic acid being the preferred agent for hypercalcemia treatment in multiple myeloma patients, as recommended by the National Comprehensive Cancer Network 1
Ensure calcium and vitamin D3 supplementation for all patients receiving intravenous bisphosphonates to prevent hypocalcemia, as suggested by Haematologica 4
Monitor renal function closely by measuring creatinine clearance, serum electrolytes, and urinary albumin in all patients receiving bisphosphonate therapy, according to Haematologica 4

Continue bone-targeting treatment (bisphosphonates or denosumab) for up to 2 years in multiple myeloma patients; continuation beyond 2 years should be based on clinical judgment, as recommended by the National Comprehensive Cancer Network 1
Denosumab is preferred in patients with renal disease, according to the National Comprehensive Cancer Network 1
For multiple myeloma patients with painful osteolytic lesions, consider radiotherapy (30 Gy in 10-15 fractions), as suggested by Haematologica 4
Consider balloon kyphoplasty for management of painful vertebral compression fractures, according to Haematologica 4

Renal function monitoring is critical as both conditions can cause renal impairment; adjust bisphosphonate dosing accordingly, as recommended by Haematologica 4
For patients with creatinine clearance 30-60 mL/min, use reduced doses of zoledronic acid with no change to infusion time, according to Haematologica 4
For patients with creatinine clearance <30 mL/min, avoid pamidronate and zoledronic acid; consider clodronate if creatinine clearance is >12 mL/min, as suggested by Haematologica 4
Perform baseline dental examination and monitor for osteonecrosis of the jaw (ONJ) in all patients receiving bone-modifying agents, as recommended by the National Comprehensive Cancer Network and Haematologica 1, 4
If ONJ develops, discontinue bisphosphonates until healing occurs, according to Haematologica 4

Evaluate renal function regularly, especially in patients receiving bisphosphonates, as recommended by Haematologica 4
Assess response to multiple myeloma therapy through standard criteria, according to the National Comprehensive Cancer Network 1

Avoid delaying systemic anti-myeloma therapy for radiation therapy; they can often be given concurrently with careful monitoring for toxicities, as recommended by the National Comprehensive Cancer Network 1